Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)

 Full screen view
Filter results: >>>>
Cell line Drug name Experimental replicate Timepoint Drug concentration Live cell count Average live cell count, DMSO control Average live cell count (time = 0) Log10(drug concentration) GR value Relative cell count (treatment versus DMSO) Cell doublings (DMSO control) Experiment name
HCC1806 Alpelisib 2 72
1.0
 11213.0 11894.0 1643.3
0.0
 0.959 0.943 2.856
HCC1806 BYL719 0 2 72
HCC1806 Alpelisib 2 72
3.2
 10596.3 11894.0 1643.3
0.505
 0.921 0.891 2.856
HCC1806 BYL719 0 2 72
HCC1806 CAL-101 2 72
0.001
 11230.8 11282.8 1643.3
-3.0
 0.997 0.995 2.779
HCC1806 CAL101 0 2 72
HCC1806 CAL-101 2 72
0.0032
 11273.8 11282.8 1643.3
-2.49
 0.999 0.999 2.779
HCC1806 CAL101 0 2 72
HCC1806 CAL-101 2 72
0.01
 11404.3 11282.8 1643.3
-2.0
 1.010 1.010 2.779
HCC1806 CAL101 0 2 72
HCC1806 CAL-101 2 72
0.032
 11305.3 11282.8 1643.3
-1.49
 1.000 1.000 2.779
HCC1806 CAL101 0 2 72
HCC1806 CAL-101 2 72
0.1
 11409.3 11282.8 1643.3
-1.0
 1.010 1.010 2.779
HCC1806 CAL101 0 2 72
HCC1806 CAL-101 2 72
0.32
 11440.8 11282.8 1643.3
-0.495
 1.010 1.010 2.779
HCC1806 CAL101 0 2 72
HCC1806 CAL-101 2 72
1.0
 11624.3 11282.8 1643.3
0.0
 1.020 1.030 2.779
HCC1806 CAL101 0 2 72
HCC1806 CAL-101 2 72
3.2
 11994.0 11282.8 1643.3
0.505
 1.040 1.060 2.779
HCC1806 CAL101 0 2 72
HCC1806 Everolimus 2 72
0.001
 10053.0 12020.5 1643.3
-3.0
 0.879 0.836 2.871
HCC1806 Everolimus 0 2 72
HCC1806 Everolimus 2 72
0.0032
 9348.8 12020.5 1643.3
-2.49
 0.832 0.778 2.871
HCC1806 Everolimus 0 2 72
HCC1806 Everolimus 2 72
0.01
 9417.5 12020.5 1643.3
-2.0
 0.837 0.783 2.871
HCC1806 Everolimus 0 2 72
HCC1806 Everolimus 2 72
0.032
 9329.3 12020.5 1643.3
-1.49
 0.831 0.776 2.871
HCC1806 Everolimus 0 2 72
HCC1806 Everolimus 2 72
0.1
 9054.3 12020.5 1643.3
-1.0
 0.812 0.753 2.871
HCC1806 Everolimus 0 2 72
HCC1806 Everolimus 2 72
0.32
 9042.0 12020.5 1643.3
-0.495
 0.811 0.752 2.871
HCC1806 Everolimus 0 2 72
HCC1806 Everolimus 2 72
1.0
 8742.8 12020.5 1643.3
0.0
 0.790 0.727 2.871
HCC1806 Everolimus 0 2 72
HCC1806 Everolimus 2 72
3.2
 8863.5 12020.5 1643.3
0.505
 0.799 0.737 2.871
HCC1806 Everolimus 0 2 72
HCC1806 Pictilisib 2 72
0.001
 11432.3 11984.0 1643.3
-3.0
 0.967 0.954 2.866
HCC1806 GDC0941 0 2 72
HCC1806 Pictilisib 2 72
0.0032
 11408.5 11984.0 1643.3
-2.49
 0.966 0.952 2.866
HCC1806 GDC0941 0 2 72
HCC1806 Pictilisib 2 72
0.01
 11154.5 11984.0 1643.3
-2.0
 0.951 0.931 2.866
HCC1806 GDC0941 0 2 72
HCC1806 Pictilisib 2 72
0.032
 11917.8 11984.0 1643.3
-1.49
 0.996 0.994 2.866
HCC1806 GDC0941 0 2 72
HCC1806 Pictilisib 2 72
0.1
 11495.5 11984.0 1643.3
-1.0
 0.971 0.959 2.866
HCC1806 GDC0941 0 2 72
HCC1806 Pictilisib 2 72
0.32
 11380.8 11984.0 1643.3
-0.495
 0.964 0.950 2.866
HCC1806 GDC0941 0 2 72
HCC1806 Pictilisib 2 72
1.0
 10951.3 11984.0 1643.3
0.0
 0.938 0.914 2.866
HCC1806 GDC0941 0 2 72